ArticleBMC cancer2026
Multi-omics characterization of C4orf19 in HNSCC: constructing prognostic signatures for immunotherapy and chemotherapy response prediction.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundsC4orf19, a protein encoded by an open reading frame on human chromosome 4, exhibits aberrant expression in various tumors and is linked to patient prognosis, though its role in head and neck squamous cell carcinoma (HNSCC) remains unclear.
methodsTCGA and GEO datasets were analyzed to evaluate the prognostic value of C4orf19 in HNSCC. Functional assays (EdU, immunofluorescence, and CCK-8) were used to assess the effects of C4orf19 knockdown on tumor cell proliferation. Drug sensitivity analyses using the GDSC database and 5-fluorouracil (5-FU) chemosensitization experiments were performed. Bioinformatics approaches (CIBERSORT, ssGSEA, xCell, and maftools) were applied to explore associations between C4orf19 expression, the tumor microenvironment (TME), immune checkpoints, and tumor mutational burden (TMB).
resultsC4orf19 was downregulated in HNSCC patients and was associated with a poor prognosis. While C4orf19 knockdown did not affect proliferation of HNSCC cells, it enhanced 5-FU sensitivity. Mechanistically, C4orf19 may influence immunotherapy efficacy by modulating immune checkpoint gene expression, remodeling TME, and regulating TMB. These findings suggest that C4orf19 expression may serve as a predictive biomarker for immunotherapy response in HNSCC patients.
conclusionsC4orf19 expression shows potential as a predictive biomarker for immunotherapy response in HNSCC patients. The study highlights its role in enhancing chemosensitization and predicting immunotherapy efficacy, positioning C4orf19 as a promising prognostic biomarker and therapeutic predictor in HNSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.